SOPHiA GENETICS SA Debt to Equity Ratio 2020-2026 | SOPH
Current and historical debt to equity ratio values for SOPHiA GENETICS SA (SOPH) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. SOPHiA GENETICS SA debt/equity for the three months ending June 30, 2026 was 0.58.
| SOPHiA GENETICS SA Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2026-06-30 | $0.12B | $0.08B | 1.39 |
| 2026-03-31 | $0.11B | $0.05B | 2.44 |
| 2025-12-31 | $0.12B | $0.05B | 2.46 |
| 2025-09-30 | $0.10B | $0.06B | 1.69 |
| 2025-06-30 | $0.10B | $0.08B | 1.32 |
| 2025-03-31 | $0.06B | $0.09B | 0.71 |
| 2024-12-31 | $0.06B | $0.10B | 0.61 |
| 2024-09-30 | $0.06B | $0.11B | 0.57 |
| 2024-06-30 | $0.06B | $0.12B | 0.49 |
| 2024-03-31 | $0.05B | $0.13B | 0.36 |
| 2023-12-31 | $0.06B | $0.15B | 0.36 |
| 2023-09-30 | $0.05B | $0.16B | 0.30 |
| 2023-06-30 | $0.05B | $0.17B | 0.30 |
| 2023-03-31 | $0.05B | $0.19B | 0.26 |
| 2022-12-31 | $0.04B | $0.20B | 0.22 |
| 2022-09-30 | $0.05B | $0.21B | 0.22 |
| 2022-06-30 | $0.05B | $0.23B | 0.22 |
| 2022-03-31 | $0.05B | $0.25B | 0.18 |
| 2021-12-31 | $0.05B | $0.28B | 0.16 |
| 2021-09-30 | $0.05B | $0.29B | 0.16 |
| 2021-06-30 | $0.03B | $0.07B | 0.46 |
| 2021-03-31 | $0.03B | $0.08B | 0.36 |
| 2020-12-31 | $0.03B | $0.10B | 0.31 |
| 2020-09-30 | $0.00B | $0.00B | 0.00 |
| 2020-06-30 | $0.00B | $0.00B | 0.00 |
| 2020-03-31 | $0.00B | $0.00B | 0.00 |
| 2019-12-31 | $0.03B | $0.02B | 1.32 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.669B | $0.077B |
| SOPHiA GENETICS SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM(TM) Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. SOPHiA GENETICS SA is based in BOSTON. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $42.890B | 42.79 |
| Tempus AI (TEM) | United States | $12.625B | 0.00 |
| 10x Genomics (TXG) | United States | $9.470B | 0.00 |
| Hinge Health (HNGE) | United States | $7.563B | 72.66 |
| Hims & Hers Health (HIMS) | United States | $6.533B | 0.00 |
| Doximity (DOCS) | United States | $4.624B | 28.50 |
| Heartflow (HTFL) | United States | $4.200B | 0.00 |
| IRhythm Holdings (IRTC) | United States | $3.686B | 243.09 |
| Privia Health (PRVA) | United States | $2.602B | 97.00 |
| Clover Health Investments (CLOV) | United States | $2.422B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $2.103B | 32.05 |
| Butterfly Network (BFLY) | United States | $1.933B | 0.00 |
| Schrodinger (SDGR) | United States | $1.767B | 0.00 |
| Omnicell (OMCL) | United States | $1.475B | 21.06 |
| Azenta (AZTA) | United States | $1.455B | 79.07 |
| Enovis (ENOV) | United States | $1.076B | 5.57 |
| Talkspace (TALK) | United States | $0.879B | 0.00 |
| Phreesia (PHR) | United States | $0.636B | 34.13 |
| Veradigm (MDRX) | United States | $0.597B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.595B | 0.00 |
| Claritev (CTEV) | United States | $0.569B | 0.00 |
| Evolent Health (EVH) | United States | $0.423B | 0.00 |
| Carlsmed (CARL) | United States | $0.418B | 0.00 |
| Senseonics Holdings (SENS) | United States | $0.379B | 0.00 |
| CapsoVision (CV) | United States | $0.300B | 0.00 |
| Standard BioTools (LAB) | United States | $0.278B | 0.00 |
| American Well (AMWL) | United States | $0.221B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.147B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.130B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.117B | 0.00 |
| CareCloud (CCLD) | United States | $0.089B | 6.53 |
| Pulmonx (LUNG) | United States | $0.084B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.063B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.060B | 0.00 |
| Outset Medical (OM) | United States | $0.059B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.055B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.050B | 0.00 |
| Precipio (PRPO) | United States | $0.048B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.034B | 0.00 |
| 111 (YI) | China | $0.030B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.025B | 0.00 |
| HeartBeam (BEAT) | United States | $0.023B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.020B | 0.00 |
| DataMeds AI (MEDS) | United States | $0.019B | 0.00 |
| HeartSciences (HSCS) | United States | $0.018B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.010B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.010B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.008B | 0.00 |
| ITonic Holdings (ITOC) | China | $0.005B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.001B | 0.00 |
| PROFUSA (PFSA) | United States | $0.001B | 0.00 |
| Zhongchao (ZCMD) | China | $0.001B | 0.00 |
| TruBridge (TBRG) | United States | $0.000B | 0.00 |